Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group
Until July 1, 2026, Medicare Part D plans could cover GLP-1 drugs only for approved diagnoses such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea but not for weight management alone
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management, with some now approved for chronic weight management
No hay consenso universal
This effect makes Semaglutide particularly useful for weight loss
Heres who might benefit most: People with insulin resistance or metabolic syndrome who have chronically elevated insulin levels that increase the production of artery-damaging cholesterol particles People with fatty liver disease and dyslipidemia (abnormal amount of fats in the blood) who need to lower inflammation and stress on the liver, bringing down high triglycerides and inhibiting production of artery-damaging cholesterol particles People whose blood work shows elevated levels of these biomarkers : ApoB : The total count of all plaque forming particles in the blood